Immutep presents positive TACTI-mel melanoma trial data
Filed with ASX · · 23 pages · English
SYDNEY, AUSTRALIA – October 15, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase I clinical study combining its lead product candidate, eftilagimod alpha (“efti” or “IMP321”) with KEYTRUDA® (pembrol
Story so far
Earlier from Immutep
- Immutep receives A$2.5M R&D French Tax Incentive
- Immutep expands Part A of TACTI-002 due to positive data
- Immutep to receive GBP4M Milestone Payment from GSK
- Japanese patent granted for LAG525 antibody
- Immutep granted European patent for IMP321 in cancer
Later from Immutep
- Appendix 4C - quarterly
- Immutep announces European patent grant for LAG525 antibody
- INSIGHT-004 clinical trial update
- Immutep expands Part C of TACTI-002 due to positive data
- Immutep Activities Report
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep